Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Immuno-PRISM (PRecision Intervention Smoldering Myeloma) — Stella

Home/High-risk Smoldering Multiple Myeloma/Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

View on ClinicalTrials.gov

Recruiting

Back to High-risk Smoldering Multiple Myeloma trials

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

Colorado Blood Cancer Institute, Denver, Colorado

Dana Farber Cancer Institute, Boston, Massachusetts

Oregon Health & Science University, Portland, Oregon

Key details

Phase

Safety & dosing

Sponsor

Irene Ghobrial, MD

Collaborators

Janssen Research & Development, LLC

Enrollment target

~52 participants

Started

August 2022

Primary completion

July 2030

Age range

18 Years and older

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.